TOR1 Antibody
Product Specs
Components: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
This antibody targets a plant-specific microtubule-associated protein (MAP) that regulates cortical microtubule orientation and subsequent organ growth direction. It modulates microtubule severing, thereby influencing microtubule organization.
Relevant Research:
- TOR1's role in stabilizing microtubule crossovers, supporting viral RNA complex formation and intercellular spread. PMID: 25133612
- SPIRAL2 (SPR2) function in growth, chromosome mapping, amino acid sequence, and phylogenetic relationships with other Arabidopsis proteins. PMID: 15557095
- SPR2 and its close homolog SP2L exhibit partially overlapping expression patterns across various tissues. spr2-sp2l double mutants demonstrate enhanced right-handed helical growth. PMID: 18577573
Q&A
Table 1: Common Methodological Pitfalls and Solutions
How do spatial localization patterns impact TOR1 antibody utility in cancer studies?
-
Golgi-localized TORC1: Antibodies must distinguish between cytoplasmic and Golgi pools. In colorectal cancer, Rab1A-mTORC1 interactions occurred specifically in the Golgi, requiring high-resolution imaging .
-
Nuclear vs. cytoplasmic roles: Validate with fractionation assays. TOR1 regulates RNA Pol I localization in the nucleolus, necessitating nuclear-cytoplasmic separation .
What advanced techniques resolve contradictions in TOR1-mediated signaling data?
-
Proximity ligation assays (PLA): Detect direct protein interactions in situ, reducing false positives from co-IP .
-
Single-cell RNA sequencing: Identify heterogeneity in TOR1 expression across cell populations, addressing variability in bulk assays .
-
CRISPR-Cas9 tagging: Endogenously tag TOR1 to bypass antibody limitations in certain models .
How can researchers optimize TOR1 antibody protocols for non-model organisms?
-
Epitope mapping: Compare conserved regions across species. For example, TbTOR1 shares 28% identity with human mTOR, requiring custom antibody validation .
-
Cross-validation: Use orthogonal methods (e.g., metabolic labeling for protein synthesis) to confirm antibody-based findings .
What biomarkers correlate with TOR1 antibody efficacy in preclinical models?
How do post-translational modifications affect TOR1 antibody performance?
-
Phosphorylation at regulatory sites (e.g., Ser/Thr residues) can alter epitope accessibility. Use phosphatase-treated lysates to assess modification-dependent binding .
-
Ubiquitination or SUMOylation may require specialized lysis buffers (e.g., inclusion of N-ethylmaleimide) .
